Literature DB >> 10408560

Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes.

R J Caselli1, N R Graff-Radford, E M Reiman, A Weaver, D Osborne, J Lucas, A Uecker, S N Thibodeau.   

Abstract

OBJECTIVE: To determine, in a cross-sectional evaluation of nondemented individuals, if age-related memory decline is influenced by apolipoprotein E (apoE) genotype.
BACKGROUND: The apoE-4 allele is an important risk factor for AD. PET in cognitively normal apoE-4 carriers (mean age, 56 years) shows reduced cerebral metabolism suggestive of very early AD that precedes clinically evident memory loss or MRI-based hippocampal atrophy.
METHODS: Tests of immediate and delayed recall (primary outcome measures) and other neuropsychological measures (secondary outcome measures) were given to three genetically defined groups of cognitively normal individuals (age, 49 to 69 years) including apoE-4 homozygotes (n = 25), apoE-4 heterozygotes (n = 25, all epsilon3/4), and apoE-4 noncarriers (n = 50). Groups were matched for age, gender, and educational background. Cross-sectional comparisons between the genetic subgroups of the relationship between age and test score were performed for each neuropsychological measure.
RESULTS: There were no intergroup differences in mean scores on any neuropsychological measure, but tests sensitive to immediate and delayed recall showed a significant negative correlation with age in the apoE-4 homozygote group relative to the noncarrier group.
CONCLUSION: Consistent with previous neuropsychological studies of early AD, this cross-sectional study suggests that age-related memory decline occurs earlier in cognitively healthy apoE-4 homozygotes than in apoE-4 heterozygotes and noncarriers, and precedes clinically detectable AD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408560     DOI: 10.1212/wnl.53.1.201

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

1.  Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene.

Authors:  P M Greenwood; T Sunderland; J L Friz; R Parasuraman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 2.  Neuronutrition and Alzheimer's disease.

Authors:  Balenahalli N Ramesh; T S Sathyanarayana Rao; Annamalai Prakasam; Kumar Sambamurti; K S Jagannatha Rao
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Asymmetry in auditory and spatial attention span in normal elderly genetically at risk for Alzheimer's disease.

Authors:  Mark W Jacobson; Dean C Delis; Mark W Bondi; David P Salmon
Journal:  J Clin Exp Neuropsychol       Date:  2005-02       Impact factor: 2.475

Review 4.  Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease.

Authors:  Elizabeth W Twamley; Susan A Legendre Ropacki; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2006-09       Impact factor: 2.892

5.  Rhinal hypometabolism on FDG PET in healthy APO-E4 carriers: impact on memory function and metabolic networks.

Authors:  Mira Didic; Olivier Felician; Natalina Gour; Rafaelle Bernard; Christophe Pécheux; Olivier Mundler; Mathieu Ceccaldi; Eric Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

Review 6.  Human cerebral neuropathology of Type 2 diabetes mellitus.

Authors:  Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery
Journal:  Biochim Biophys Acta       Date:  2008-08-22

Review 7.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

8.  The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation.

Authors:  Sterling C Johnson; Taylor W Schmitz; Mehul A Trivedi; Michele L Ries; Britta M Torgerson; Cynthia M Carlsson; Sanjay Asthana; Bruce P Hermann; Mark A Sager
Journal:  J Neurosci       Date:  2006-05-31       Impact factor: 6.167

Review 9.  Use of genetic variation as biomarkers for Alzheimer's disease.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

10.  Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population.

Authors:  A G Yip; C Brayne; D Easton; D C Rubinsztein
Journal:  J Med Genet       Date:  2002-09       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.